

Available online at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/scr

Cardiac regeneration based on mechanisms of cardiomyocyte proliferation and differentiation

Samuel E. Senyo^{a,b,c,d}, Richard T. Lee^{a,b,c,d}, Bernhard Kühn^{c,d,e,f,*}^a Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA^b Brigham Regenerative Medicine Center, Cambridge, MA 02139, USA^c Harvard Stem Cell Institute, Cambridge, MA 02138, USA^d Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA^e Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA^f Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

Received 18 December 2013; received in revised form 10 September 2014; accepted 16 September 2014

Abstract Cardiomyocyte proliferation and progenitor differentiation are endogenous mechanisms of myocardial development. Cardiomyocytes continue to proliferate in mammals for part of post-natal development. In adult mammals under homeostatic conditions, cardiomyocytes proliferate at an extremely low rate. Because the mechanisms of cardiomyocyte generation provide potential targets for stimulating myocardial regeneration, a deep understanding is required for developing such strategies. We will discuss approaches for examining cardiomyocyte regeneration, review the specific advantages, challenges, and controversies, and recommend approaches for interpretation of results. We will also draw parallels between developmental and regenerative principles of these mechanisms and how they could be targeted for treating heart failure.

© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Introduction

Cardiomyopathies constitute a group of heart muscle diseases of varied etiology that are treatable with medical therapies, but cardiac function generally declines despite therapy. Most cardiomyopathies at the stage of heart failure exhibit cardiomyocyte loss. Adult mammals do not sufficiently regenerate cardiomyocytes to compensate for lost

cardiomyocytes. Cardiac transplantation is the only proven method to replace lost cardiomyocytes. In light of insufficient numbers of donor organs, stimulating myocardial regeneration offers a potential strategy for treating heart failure.

In contrast to adult mammals, amphibians, reptiles, and zebrafish regenerate cardiomyocytes after myocardial injury (Jopling et al., 2010; Oberpriller and Oberpriller, 1974). The research community has directed attention to two principal strategies to regenerate myocardium: Use of stem and progenitor cells to repair damaged myocardium and enhancement of endogenous regenerative mechanisms (Garbern and Lee, 2013). This review focuses on endogenous regeneration mechanisms by cardiomyocyte proliferation.

* Corresponding author at: Children's Hospital of Pittsburgh of UPMC, Richard King Mellon Institute for Pediatric Research and Division of Cardiology, 4401 Penn Ave, Pittsburgh, PA 15224-1334, USA.
E-mail address: Bernhard.kuhn@CHP.edu (B. Kühn).

<http://dx.doi.org/10.1016/j.scr.2014.09.003>

1873-5061/© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Historical and current perspectives in cardiac regeneration

Anecdotal reports over the past 100 years have shown mitoses of cardiomyocyte nuclei; however, evidence for cardiomyocyte division remained elusive. The first systematic and quantitative examinations of the cellular mechanisms of human heart growth were published in the 1950s (Linzbach, 1950; Linzbach, 1960). One study examined the increase of cardiomyocyte cross-sectional area in the left ventricular papillary muscle in humans and concluded that cardiomyocyte enlargement could fully account for physiologic myocardial growth between birth and adulthood (Linzbach, 1950, 1960). Because examining orthogonally sectioned papillary muscles is associated with biases, the validity of extrapolating these results to the entire heart is limited. Still, historically, the mammalian heart has been viewed as a post-mitotic organ in which the primary parenchymal cells, cardiomyocytes, do not increase in number after birth (Zak, 1973; Linzbach, 1950).

Additional classical studies of cardiomyocyte proliferation used microscopy to visualize mitotic figures. However, these approaches probably did not have the precision necessary for definitive visualization of cardiomyocyte cytokinesis nor the throughput for quantifying rare events. Although not conclusive, these studies led to two paradigms: First, unlike skeletal muscle, the adult heart does not have progenitors supporting the generation of new cardiomyocytes. The second paradigm argued that there is a single cellular mechanism of post-natal developmental and pathological heart growth: cardiomyocyte enlargement (Rumyantsev and Carlson, 1991; Borisov and Claycomb, 1995). In the latter-20th century, technical advances, including use of confocal microscopy to visualize cell cycle events, automated analyses of large cell populations, and genetic and metabolic labeling for cellular fate mapping, have provided new data. This has advanced a new cellular paradigm, which includes adult cardiomyocyte renewal, while incorporating the significant role that cardiomyocyte enlargement plays in physiologic and pathologic heart growth.

The recognition of endogenous cardiomyocytes as a source for new cardiomyocytes raises the possibility of stimulating this process for myocardial repair. By understanding the mechanisms limiting the regenerative response of mammalian myocardium, therapeutic strategies could be developed. To realize this therapeutic potential, the scientific community needs to address questions involving the precise cellular source for new cardiomyocytes, the regulating signaling pathways, the underlying cellular mechanisms, and the genesis rates and dynamics.

Mechanisms of cardiomyocyte regeneration pose challenges for investigation

Cardiomyocyte generation in the adult mammalian heart is a slow process compared with the blood, skin, and the digestive system, which makes it difficult to characterize turnover dynamics. In situ time lapse imaging of the beating mammalian heart at cellular resolution is technically challenging (Hashimoto et al., 2014; Hesse et al., 2012). Myocardial biopsies from patients provide only a small amount of tissue

for analysis. The cellular heterogeneity and close spatial packing of cells in the myocardium can obscure the identification of cardiomyocyte nuclei from neighboring non-cardiomyocytes (Soonpaa and Field, 1997; Soonpaa et al., 2012). Perhaps the most challenging aspect is that cardiomyocytes exhibit non-proliferative cell cycles that increase the DNA content without cell division. Despite these intrinsic biological features that complicate studying regeneration, several new methods have enabled the advance of our understanding of cardiomyocyte proliferation.

Classical and new methods have advanced cardiac regeneration research

Labeled thymidine and thymidine analogs are stably incorporated into the genome during DNA synthesis and can be used to record cell cycle events. The use of tritiated thymidine is limited by potential radioactive toxicity due to long-term administration and by lower spatial resolution of visualization by autoradiography, compared with confocal microscopy (Soonpaa and Field, 1997). The early manual analysis of autoradiographs of tritiated thymidine in isolated cardiomyocytes fits with recent studies almost 2 decades later (Soonpaa and Field, 1997; Li et al., 1996; Senyo et al., 2013; Soonpaa et al., 1996). Thymidine analogs such as bromo-deoxyuridine (BrdU) have also been administered for up to several weeks for detecting cardiomyocyte cell cycle activity. Though high concentrations of BrdU can affect cell proliferation and differentiation, adverse effects were not reported with long-term labeling (Wilson et al., 2008; Malliaras et al., 2013). Similar to Soonpaa et al. with a tritium label, Li et al., using a single BrdU injection, observed progressive loss of cardiomyocyte-DNA synthesis in rats within ten days of birth (Li et al., 1996; Soonpaa et al., 1996). However, it should be noted that using Ki67 as a marker, Walsh et al. detected cell cycle activity in cardiomyocyte nuclei in mice up to 21 days of age (Walsh et al., 2010). Naqvi et al. detected BrdU uptake and markers of mitosis and cytokinesis in cardiomyocytes in 13–15 day-old mice (Naqvi et al., 2014).

In the adult heart, Soonpaa et al. examined mice 2 h after administration of tritiated thymidine (3 injections, 12-hour intervals) and determined a 0.0005% labeling frequency of cardiomyocytes expressing a transgenic marker from the α -MHC-promoter (Soonpaa and Field, 1997). More recently, the use of long term BrdU labeling demonstrated a low basal activity of cardiomyocyte proliferation though an order higher than previously reported (Li et al., 1996; Malliaras et al., 2013).

Antibodies raised against markers of the cell cycle can be used for visualization by microscopy (e.g. Ki67 for G1, S, G2 and M-phase, phospho-histone3 for M-phase, Aurora B kinase for cytokinesis) (Senyo et al., 2013; Malliaras et al., 2013; Ellison et al., 2013; Mollova et al., 2013). Antibody-based detection has the advantage of broad applicability, but is potentially susceptible to false-positives and -negatives. These issues can be addressed with appropriate negative controls. It should be noted that Ki-67 is present in G1-, S-, G2-, and M-phase of the cell cycle. Thus, for mechanistic studies, Ki-67 assays should be combined with other, more specific cell cycle markers.

Automated systems provide an unbiased approach for sampling large numbers of cardiomyocytes, but so far, they require dispersed cells. Flow cytometry (FACS) and laser scanning cytometry (LSC) offer high throughput methods to detect and quantify antibody labeling of isolated cardiomyocytes or nuclei (Malliaras et al., 2013; Walsh et al., 2010; Mollova et al., 2013). Recently, we examined cardiomyocyte cycling in humans using the M-phase marker phospho-histone3 and used LSC for read-out. This demonstrated a decrease in cardiomyocyte proliferation between birth and 20 years of life in humans (Mollova et al., 2013). We compared the LSC results with visual quantification of H3P-positive cardiomyocyte nuclei on stained cryosections, which reproduced the pattern of decreasing H3P-activity between birth and 20 years (Mollova et al., 2013). LSC in humans and FACS in mice showed agreement in that the frequency of cardiomyocyte cell cycle activity decreases after birth (Walsh et al., 2010; Mollova et al., 2013).

Carbon-14 birth dating is an approach devised by the Frisen group to monitor cellular turnover in tissue (Bergmann et al., 2009). This strategy makes use of the transient increase of carbon-14 (^{14}C) in the biosphere due to a period of above ground nuclear testing that ended in the 1960s. The carbon-14 was taken up by humans through the diet and incorporated into the genomic DNA, which can be used as a time-stamp to calculate the mean birth date of a stable cell population (Bergmann et al., 2009). The carbon-14 content in cardiomyocyte nuclear DNA is quantified using accelerator mass spectrometry (AMS, which has a lower detection limit of 10^{-21} moles). The mean age of cardiomyocytes is then compared with the age of the source individual. This indicated generation of new cardiomyocytes at a rate of ~1% after 25 years of age. The fidelity of this approach depends on the quality of cardiomyocyte nuclei isolated from post-mortem myocardium. AMS provides a tissue-average, which poses a challenge since in cardiomyocytes, S-phase can be connected with cell division and differentiation. Hence, the analysis relied on additional assumptions that had to be made for mathematical modeling of the data (Bergmann et al., 2009), including assumptions about potential changes of the number of cardiomyocytes after birth, rates of cardiomyocyte cell death, and the extent of non-proliferative cell cycles (multinucleation and ploidy) with age (Elser and Margulies, 2012).

Fate mapping with genetic tags has been used to label distinct cell populations to determine the source of new cells with time or intervention. Multiple groups have used the α -MHC promoter driven Cre model crossed with reporter lines to assay the role of progenitor cells in the generation of new cardiomyocytes after injury (Senyo et al., 2013; Malliaras et al., 2013; Ellison et al., 2013). After tamoxifen induction, a majority of differentiated cardiomyocytes is labeled with a reporter such as green fluorescent protein (GFP) or LacZ (Senyo et al., 2013; Porrello et al., 2012). Using this technique, we have demonstrated that during normal aging in mice, the percent of preexisting cardiomyocytes, indicated by the percentage of GFP-positive cardiomyocytes, remains unchanged (Hsieh et al., 2007). Influx of cardiomyocytes generated from undifferentiated progenitor cells should result in a decrease of the percentage of GFP-labeled (preexisting) cardiomyocytes. This "dilution" was the case after experimental myocardial infarction, leading to the conclusion that myocardial injury induced an influx of progenitor cell-derived cardiomyocytes (Hsieh et al., 2007). However, multiple other

studies showed very little or no contribution of progenitor cells to generating cardiomyocytes in adult mammals (Senyo et al., 2013; Malliaras et al., 2013; Ellison et al., 2013; Porrello et al., 2012; Loffredo et al., 2011). Considering one specific progenitor type, Ellison et al. reported a 0.15% generation rate for c-kit progenitor-derived cardiomyocytes in a 4-week period of normal aging (Ellison et al., 2013). This contrasts with results from using a knock-in of an inducible Cre into the c-kit gene locus (van Berlo et al., 2014). This more direct approach demonstrated that c-kit positive cells do not generate cardiomyocytes in mice after birth to a significant degree (van Berlo et al., 2014). In this context, it is important to note that c-kit positive cells isolated from neonatal mice can generate cardiomyocytes (Zaruba et al., 2010). Systematic molecular characterization of myocardial c-kit cells and comparison with the cardiomyocyte lineage should help resolve this controversy.

Potential explanations of our discrepant results with the genetic α -MHC-MerCreMer/ZEG fate mapping techniques include cardiomyocyte toxicity due to high expression levels of Cre (Lexow et al., 2013; Bersell et al., 2013). However, we did not observe these effects in the 14-day induction protocol with 5-hydroxy-tamoxifen (Loffredo et al., 2011; Lexow et al., 2013; Bersell et al., 2013; Koitabashi et al., 2009). A concern of genetic tags expressed under control of cell-specific promoters is the dependence on the fidelity of transcriptional activity. In addition, it may be possible that the labeled cell population is phenotypically heterogenous. This possibility must be considered when the genetic labeling technique does not label the entire cell population, as is the case with the α -MHCMerCreMer mice (Sohal et al., 2001). Other genetic approaches such as retrospective clonal assays utilize random labeling of precursor cells and have been used to address lineage in early cardiac development (Ali et al., 2014; Buckingham and Meilhac, 2011). This system selectively labels daughter cells of mononucleated cells in divergent fluorescent tags so that one cell is labeled with red and the other with green. Using two transgenic models for a cardiomyocyte specific source and a non-discriminate source, respectively, Ali et al. demonstrated that very few new mononucleated cardiomyocytes are generated primarily from pre-existing cardiomyocytes (Ali et al., 2014). Genetic labeling remains one of the most powerful approaches to monitor cell population dynamics, if applied appropriately.

Stable isotopes can be used to mark biological molecules for monitoring cell cycle activity over long periods. Stable isotope-labeled biomolecules are integrated into cells without disrupting biological functions. The safety of stable isotope labels allows long-term labeling strategies to both characterize events over extended periods and record rare events. The read-out utilizes a high-resolution analytical imaging system called multi-isotope imaging mass spectrometry (MIMS). The MIMS platform was developed by Dr. Claude Lechene at the National Resource for Imaging Mass Spectrometry as a quantitative approach to image biological processes (Steinhauser and Lechene, 2013). MIMS generates detailed quantitative images based on the isotope composition of the sample surface. The spatial resolution of MIMS is similar to electron microscopy and can be used for analyzing sub-cellular structures, including chromatin, cytoplasmic proteins, and organelles. Thymidine marked with nitrogen-15 (^{15}N), the rare stable isotope of the abundant nitrogen-14) can be introduced into cell culture

media or animals and is incorporated into the genome to make an in situ record of DNA synthesis. We have used this approach for quantifying several successive cell divisions in the intestine (Steinhauser et al., 2012). In Senyo et al., we employed this approach to study cardiomyocyte turnover (Senyo et al., 2013).

Cardiomyocyte cell cycle activity decreases during post-natal development

After birth, most mammalian cardiomyocytes transition from proliferation to terminal differentiation. The terminally differentiated phenotype is commonly characterized as having no proliferative potential. Cardiomyocyte DNA-synthesis activity decreases during the first 1–2 weeks of life in rodents (Li et al., 1996; Soonpaa et al., 1996). However, flow cytometry analysis has detected cardiomyocytes positive for the cell cycle marker Ki-67 in mice up to 2–3 weeks of age (Walsh et al., 2010; Ikenishi et al., 2012). We have detected cardiomyocytes positive for the mitosis marker H3P in humans in the first 20 years of adult life, after which the activity was very low (Mollova et al., 2013). In mice, we administered isotope-labeled thymidine for 8 weeks to increase our sensitivity of detecting cardiomyocyte cell cycle activity. By MIMS analysis, we measured a 56% labeling index of cardiomyocytes with at least one cell cycle event in mice in the first 2 months of life. Using the same labeling protocol, adult mice exhibited a significant decrease of cardiomyocytes with history of cell cycle activity (0.84% over 2 months; 0.015%/day). Due to the 8 week-long duration of labeling, we could not determine the specific time pattern of cell cycle withdrawal during the neonatal period. In summary, the post-natal period during which cardiomyocyte cell cycle activity decreases is much longer in humans, as compared with mice and rats. All three species show extremely low cardiomyocyte cell cycle activity as adults.

Post-natal cardiomyocyte cell cycle activity may be associated with proliferation, resulting in a change of the number of cardiomyocytes. A study using biochemical quantification of cardiac DNA content reported an increase in cardiomyocyte number in humans after birth (Adler and Costabel, 1975). Our direct stereologic quantifications of cardiomyocyte numbers in humans demonstrated an increase from 1.1 to 3.7 billion cardiomyocytes from birth to age 20 years (Mollova et al., 2013). A recent study showed an increase of the number of cardiomyocytes in pre-adolescent mice by 40% (Naqvi et al., 2014). Manual counting of isolated cardiomyocytes in rats showed an increase from 13.6 to 22.9 billion from birth to day 3 (Li et al., 1996). In summary, post-natal cardiomyocyte proliferation has been documented in mice, rats, and humans. However, the time period during which this happens varies widely.

After birth, rodent cardiomyocytes transition from cell division to incomplete cell cycles, resulting in approximately 80–90% binucleated cardiomyocytes in adult mice and rats. Humans are borne with approximately 30% of cardiomyocytes being binucleated, and this proportion does not change significantly after birth (Mollova et al., 2013). However, in humans the ploidy of cardiomyocyte nuclei increases between birth and adulthood (Mollova et al., 2013; Adler and Costabel, 1975).

Molecular changes associated with cell cycle withdrawal have been described, but molecular mechanisms of terminal differentiation remain largely uncharacterized

The transition to the terminally differentiated phenotype is accompanied by down-regulation of cell cycle factors and up-regulation of cell cycle inhibitors (Soonpaa et al., 1996; Mollova et al., 2013; Adler and Costabel, 1975; Brooks et al., 1998; Poolman and Brooks, 1998). Cell cycle activators such as the Cdk/cyclin complex, Myc, E2F transcription factors were demonstrated to be repressed. Negative cell cycle regulators are increased, such as p21, p27, retinoblastoma protein, and cyclin-dependent kinase inhibitors (Pasumarthi and Field, 2002; Li et al., 1998; Flink et al., 1998). However, the functional relevance of these associations has not been fully characterized. Decreased cardiomyocyte cell cycle activity was shown to be associated with the increase of the tissue oxygen tension upon birth, leading to increased cardiomyocyte DNA damage (Puente et al., 2014).

Under homeostatic conditions, cardiomyocyte turnover in the mammalian heart is very low

Turnover is the dropout and generation of new cells without a change of the total number of cells in the organ, i.e. during homeostasis. The number of cardiomyocytes per heart is important when considering the rate of cardiomyocyte turnover and regeneration. Few studies have quantified the number of cardiomyocytes in human hearts (Hsieh et al., 2007; Lesauskaite et al., 2004). Using stereology, we quantified the number of cardiomyocytes in adult humans to be approximately 3.7 billion ($n = 7$), corresponding to 5.6 billion cardiomyocyte nuclei (Mollova et al., 2013). Our results are between the results from another stereology study that quantified the number of cardiomyocyte nuclei in adult humans to be 9.5 billion ($n = 6$ hearts, ref. (Tang et al., 2009)), and a study using biochemical techniques, which showed 2 billion cardiomyocytes ($n = 30$, ref. (Adler and Costabel, 1975)).

Quantification of cardiomyocyte loss is challenging. Apoptosis markers are reported to have variable sensitivity. DNA repair and postmortem enzymatic degradation may yield false-positive results with the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay (Lesauskaite et al., 2004; Saraste and Pulkki, 2000). The irreversible progression of cell death in cells expressing late stage apoptosis markers has also been called into question in several organs, including the heart (Tang et al., 2012). Thus, there is a lack of consensus for the frequency of cardiomyocyte apoptosis in normal hearts, with estimates varying by more than an order of magnitude (Lesauskaite et al., 2004; Saraste and Pulkki, 2000; Wencker et al., 2003; Chen et al., 2001; Vulapalli et al., 2002).

Cardiomyocyte turnover was quantified with different techniques. The carbon-14 birth dating strategy showed that adult humans turn over approximately 0.5% of cardiomyocytes per year (Bergmann et al., 2009). Our MIMS approach showed a turnover rate of approximately 1% in adult mice (Senyo et al., 2013). Several groups found multinucleation and polyploidy to

account for a majority of cell cycle events after the first two weeks of life in murines (Senyo et al., 2013; Malliaras et al., 2013; Walsh et al., 2010). Using immunofluorescence microscopy, we have not been able to detect cardiomyocytes in cytokinesis in adult humans (Mollova et al., 2013). Overall, reported rates of cardiomyocyte turnover in adult mice and humans are converging at approximately 1% or less per year (Senyo et al., 2013; Soonpaa et al., 1996; Mollova et al., 2013; Bergmann et al., 2009).

We have utilized the α -MHC-MerCreMer; Z/EG mice for cell lineage tracing in concert with stable isotope-labeled thymidine to detect cardiomyocytes with a history of cell cycle activity (Senyo et al., 2013). Approximately 80% of preexisting cardiomyocytes were genetically labeled with GFP by injection of 4-hydroxy-tamoxifen. We have labeled with isotope-labeled thymidine for four to ten weeks at different points after birth. We used MIMS analysis of histological sections to visualize isotope-labeled thymidine localization. We identified cardiomyocyte nuclei by staining for cardiac markers (sarcomeric actin) and nuclei (DAPI or PAS histological staining). To analyze multi-nucleated cardiomyocytes, we used fiducial marks on sections to retrieve corresponding nuclei on adjacent sections. Fluorescent in situ hybridization in at least two sections on either side of the MIMS section was used to determine ploidy. Using this method, we quantified that <1% mononucleated diploid cardiomyocytes per year in adult mice were generated.

The source of cardiomyocytes generated during turnover remains an active area of research. Data support a role for both progenitor differentiation and cardiomyocyte proliferation. A more expansive discussion of cardiogenic progenitor potential in the adult heart is described in other articles in this series of reviews. In short, several classes of progenitor cells both in development and in the adult myocardium have been reported to contribute to the generation of cardiomyocytes.

Cardiomyocyte cycling increases after myocardial injury, but does not lead to effective regeneration

In adult mice after experimental myocardial infarction, the border zone shows a 10-fold increase of cardiomyocyte cell cycle activity. As described above, the α -MHC-MerCreMer mouse in combination with Cre-reporter lines has the potential to distinguish progenitor and cardiomyocyte contributions to cardiomyocyte generation (Sohal et al., 2001). Injection of tamoxifen prior to inducing injury triggers GFP expression in cardiomyocytes. After injury, an increase of the GFP-negative percentage is interpreted as generation of cardiomyocytes derived from a progenitor pool. Using this system, Malliaras et al. demonstrated a role for proliferative cardiomyocytes in adult mouse hearts, but a larger role for progenitor cells (Malliaras et al., 2013).

Combining the Cre model with stable isotope mapping on the MIMS platform, we have found that cell cycle activity occurs primarily in preexisting cardiomyocytes (Senyo et al., 2013). While this study replicated our previous finding of the dilution of GFP+ cardiomyocytes, indicative of progenitor differentiation (Hsieh et al., 2007; Loffredo et al., 2011), we observed cell cycle activity by stable isotope labeling in preexisting cardiomyocytes in the injury border (Senyo et al.,

2013). This contrasts with our previous reports that demonstrated generation of cardiomyocytes from undifferentiated progenitor cells (Hsieh et al., 2007; Loffredo et al., 2011). These differences may be due to different long-term viability of GFP- and GFP+ cardiomyocytes, although our evaluation of short-term proliferation and apoptosis rates did not show differences.

Examining the mechanisms of cardiac regeneration when cardiomyocyte cell cycling and proliferation are active may provide new insight. Such studies were enabled by emulating the zebrafish model of excising 10–20% of the ventricular myocardium (Poss et al., 2002). This was achieved by the Sadek group in 2011 (Porrello et al., 2011; Heallen et al., 2013). The apical resection model was reported to increase cardiomyocytes in M-phase and cytokinesis in neonatal mice (Porrello et al., 2011). The authors demonstrated scarless myocardial repair and proliferation of preexisting cardiomyocytes using a Cre model combined with BrdU labeling. The aspects of scarless repair and increased cardiomyocyte cell cycle activity after apical amputation in neonatal mice have recently been challenged (Andersen et al., 2014; Sadek et al., 2014). The difference in terms of scarless repair may be due to our inability to demarcate the resection level. Given the challenges of apical resection, the myocardial infarction (MI) approach by ligation of the left anterior descending coronary artery (LAD) in the neonatal heart may provide an alternative (Haubner et al., 2012; Porrello et al., 2013). This model represents a more relevant model for inducing an injury and offers the advantage of using a defined landmark for inducing injury. However, the challenge of this technique is the need for microsurgical skills for identifying the LAD. Mastering these neonatal mouse models is required for advancing our understanding of post-natal cardiomyocyte proliferation in the setting of injury.

There is anecdotal clinical evidence that the human heart has regenerative potential. For example, an ectopic heart transplant recipient recovered normal function of the original heart, thus allowing the donor heart to be removed (Tsang et al., 2009). Examinations of the mechanisms and degree of cardiac regeneration are technically difficult in humans for ethical reasons because they require pieces of myocardium for analysis.

Mechanisms of cycling and division of differentiated cardiomyocytes

The term 'terminally differentiated cardiomyocyte' in the context of cardiac regeneration is meant to describe the cardiomyocyte phenotype that lacks proliferative capacity, that is, these cardiomyocytes do not actively cycle nor can they be stimulated to re-enter the cell cycle. In the adult mammalian heart, terminally differentiated cardiomyocytes represent the vast majority. Different explanations for the lack of proliferative capacity have been proposed: the presence of the differentiated sarcomeric cytoskeleton may prohibit cell division and the binucleated and polyploid phenotype may prevent cell cycle entry. However, cardiomyocyte mitotic figures have been reported in adult zebrafish and mice (Jopling et al., 2010; Porrello et al., 2011; Bersell et al., 2009; Kikuchi et al., 2010), suggesting

that the presence of sarcomeres may not be prohibitive to cardiomyocyte division. The mechanisms of cell cycle entry and division of adult cardiomyocytes may involve cellular dedifferentiation. Sarcomere disassembly has been reported in proliferating zebrafish and neonatal mouse and rat cardiomyocytes and correlated with distinct changes in gene expression (Li et al., 1996; Dispersyn et al., 2002; Sharov et al., 1997; Kubin et al., 2011). Oncostatin M, p130, and retinoblastoma protein regulate dedifferentiation in culture (Kubin et al., 2011; Sdek et al., 2011). Reversal of epigenetic gene silencing mechanisms may be involved with cardiomyocyte cell cycle re-entry (Tsang et al., 2009; Sdek et al., 2011; Ibrahim et al., 2012).

We have demonstrated that neuregulin-induced proliferation of differentiated adult mouse and rat cardiomyocytes occurs primarily in the mononucleated portion (Bersell et al., 2009). Most adult zebrafish cardiomyocytes are mononucleated, which is consistent with their significant proliferative activity during regeneration (Wills et al., 2008). Newt cardiomyocytes are 98% mononucleated in vivo, but in culture ~30% acquire a binucleated phenotype by way of incomplete cytokinesis (Bettencourt-Dias et al., 2003). Of these bi- and multi-nucleated newt cardiomyocytes, ~20% re-entered the cell cycle and some divided. It is important to note that bi- and multi-nucleated cardiomyocytes are exceedingly rare in newts in vivo (Bettencourt-Dias et al., 2003). In human infants and children, cardiomyocyte cell cycle activity occurs predominantly in the mononucleated fraction (Mollova et al., 2013). A recent report proposed division of binucleated cardiomyocytes in mice during the pre-adolescent growth spurt (Naqvi et al., 2014). In summary, some evidence suggests that the morphologic phenotype of cardiomyocytes with respect to mono-/binucleation may be associated with cell cycle capacity, although this association may not be strict.

What is the evidence for a distinct phenotype of differentiated cardiomyocytes that can re-enter the cell cycle? In animal models where cardiomyocyte cycling has been induced, cardiomyocytes have been described as smaller in size (Katz et al., 1992; Mahmoud et al., 2013; Chakraborty et al., 2013; Liao et al., 2001). In the border region of ischemic injury, actively cycling cardiomyocytes have been measured to be smaller in dimensions (Mollova et al., 2013; Beltrami et al., 2001). In Mollova et al., we observed cycling human cardiomyocytes in vivo to be mononucleated (Mollova et al., 2013). In mice, some mononucleated cardiomyocytes have the ability to undergo multiple rounds of division in vivo as determined by sequential labeling schemes and clustering of cardiomyocytes with a record of cell cycle (Bersell et al., 2009). We found with MIMS analysis that most cardiomyocytes with evidence for a history of division were mononucleated and diploid (Senyo et al., 2013). In summary, independent reports indicate a higher cell cycle activity in mononucleated as compared with binucleated cardiomyocytes (Senyo et al., 2013). It remains to be determined whether a proliferation-competent cardiomyocyte phenotype can be defined based on molecular characteristics.

Cultured cardiomyocytes are a useful tool for mechanistic studies. In culture, isolated adult cardiomyocytes progressively change their rod-like morphology to a flat shape coinciding with cytoskeleton reorganization (Malliaras et al., 2013; Kubin et al., 2011; Claycomb, 1985; Zhang et al.,

2010; Engel et al., 2005). This morphologic change in vitro may facilitate the ability of mitogenic stimuli to induce cell division in cardiomyocytes that in vivo may not proliferate and must be considered when interpreting the results (Bersell et al., 2009; Kubin et al., 2011; Claycomb, 1985; Zhang et al., 2010).

Stimulating cardiac regeneration by inducing cardiomyocyte proliferation

Fetal and 1-day neonatal mice exhibit regenerative capacity in response to genetically induced disease and surgical damage, respectively (Porrello et al., 2011; Drenckhahn et al., 2008). The capacity for scarless repair appears to be present in mice until the neonatal period (Porrello et al., 2011; Porrello et al., 2013; Drenckhahn et al., 2008). Within the first two weeks of life in mice (Soonpaa et al., 1996; Walsh et al., 2010) and approximately 10–20 years in humans (Mollova et al., 2013; Bergmann et al., 2009), cardiomyocytes transition from cell cycle activity to a non-cycling state. The association between cardiomyocyte cell cycle activity and regenerative potential has raised interest in modulating cardiomyocyte proliferation after the end of the regenerative period.

To regain proliferative capacity in adult cardiomyocytes, cell cycle checkpoints have been modulated with molecular interventions. Forced expression of cyclin B1-CDC2, and knockdown of p21/p27 have been shown to increase cell cycle activity of cardiomyocytes in vitro (Bicknell et al., 2004; Di Stefano et al., 2011). However, cell cycle factors do not universally activate cell division as over-expression of cyclin D1 in adult cardiomyocytes promotes DNA synthesis and multinucleation without proliferation (Soonpaa et al., 1997). In vivo, cyclin D2, but not cyclin D1 and D3, resulted in persistent cardiomyocyte DNA synthesis and reduced scarring after experimental myocardial infarction in mice (Pasumarthi et al., 2005). Similarly, transgenic expression of cyclin A2 increased cardiomyocyte cycling and myocardial regeneration (Chaudhry et al., 2004; Woo et al., 2006). Overexpression of the adenoviral oncogene E1A induced cardiomyocyte cycling, followed by apoptosis (Liu and Kitsis, 1996). Overexpression of the transcription factor E2F-1 increased cardiomyocyte apoptosis, whereas overexpression of E2F4 stimulated cardiomyocyte cycling in vivo (Agah et al., 1997; Yurkova et al., 2008; Ebelt et al., 2008). Knock-out of the regulators of the E2F transcription factors, the pocket proteins Rb and p107, increased cardiomyocyte cycling (Sdek et al., 2011; MacLellan et al., 2005). Chemical inhibition and genetic knockout of GSK3 β led to increased cardiomyocyte cycling (Tseng et al., 2006; Kerkela et al., 2008), which indicates the Wnt signaling pathway as a potential target for stimulating cardiac regeneration.

Recapitulating developmental signaling pathways in differentiated cardiomyocytes has the potential to stimulate proliferation. Under this premise, developmental signaling pathways should be present in differentiated cardiomyocytes and available for activation. For example, developmentally expressed cell surface receptors could be stimulated with extracellular factors. Neuregulin and its receptors on cardiomyocytes, the receptor tyrosine kinases ErbB2 and ErbB4 regulate developmental cardiomyocyte proliferation and

differentiation (Wadugu and Kuhn, 2012). Administration of neuregulin and oncostatin M, an extracellular factor activating cytokine receptors has been shown to stimulate cardiomyocyte proliferation (Bersell et al., 2009; Kubin et al., 2011). In addition, intracellular components of developmental signaling pathways can be targeted. For example, modifications of positive and negative regulators of the Hippo pathway have been shown to enhance neonatal and adult mouse cardiomyocyte cycling (Heallen et al., 2013; von Gise et al., 2012; Xin et al., 2011).

Delivery of neuregulin1 (Nrg1), fibroblast growth factor (FGF1) with pharmacologic p38 MAP kinase blockade, and periostin peptide has been demonstrated to promote myocardial repair (Bersell et al., 2009; Engel et al., 2006; Kuhn et al., 2007). We have shown that administration of recombinant NRG1 induces cell cycle and division markers in cardiomyocytes, resulting in generation of new cardiomyocytes and improved function (Bersell et al., 2009). We have also demonstrated that local delivery of a peptide of periostin in rats immediately after MI increased cardiomyocyte proliferation, reduced scar formation, and improved myocardial function (Kuhn et al., 2007). Mice with a germline knockout of the periostin gene showed a very mild general phenotype and were viable (Rios et al., 2005). Other periostin germline knockouts did not reduce cardiomyocyte cycling or myocardial growth, but showed reduced scar formation and impaired repair after myocardial infarction (Shimazaki et al., 2008; Lorts et al., 2009). Overexpression of the full-length periostin gene under control of the α -MHC promoter in differentiated cardiomyocytes did not increase cardiomyocyte cell cycle activity (Lorts et al., 2009). In this context, is important to note that normally, cardiomyocytes do not express the periostin gene. In addition, there is evidence for functional significance of a periostin splice variant, but a definitive structure–function relationship has not yet been achieved (Litvin et al., 2006). We have subsequently reported periostin peptide-stimulated cardiomyocyte mitosis in large animals (Polizzotti et al., 2012). This was recapitulated in an independent analysis, which also showed a reduction of scar formation, but increased fibrosis on microscopic analysis (Ladage et al., 2013). In summary, the apparent discrepancy between administration of periostin peptide and manipulation of the full-length gene with respect to cardiomyocyte cell cycling may be associated with fundamental differences of the activated mechanisms, possibly due to specifics of the molecular strategy (truncated peptide vs. full-length gene). These differences can also be due to timing (acute peptide therapy vs. chronic overexpression by transgene) and heterologous expression in cardiomyocytes. This comparison indicates that specifics of molecular interventions matter and should ideally be addressed with side-by-side experimentation.

Discussion

Multiple studies have demonstrated that adult mammals renew cardiomyocytes at a very low rate from a cellular source of pre-existing cardiomyocytes (Senyo et al., 2013; Malliaras et al., 2013; Ellison et al., 2013; Mollova et al., 2013). Endogenous progenitor cells may play a role in therapeutic approaches. The 2012 POSEIDON clinical trial shows some potential for autologous mesenchymal cells in patients with ischemic cardiomyopathy (Hare et al., 2012; Traverse et al., 2012).

The release of cell cycle blocks in adult cardiomyocytes and progenitor cell activation can facilitate an increase in cell cycle activity (Malliaras et al., 2013; Mollova et al., 2013; Loffredo et al., 2011; Mahmoud et al., 2013). An emerging line of research seeks to define endogenous mechanisms of cardiomyocyte proliferation in the context of post-natal development and in response to neonatal injury (Garbern and Lee, 2013).

Establishing standards for defining cardiac regeneration would be useful for comparing different studies and ultimately for advancing the field. These standards should be high and broadly accepted. When using metabolic labels (for example BrdU and labeled thymidine preparations), the labeling strategy should be clearly described, and the labeling kinetics should be measured (blood concentrations, effectiveness of cellular labeling). Assay sensitivities should be quantified and reported. Cardiomyocyte cell cycle activity should be measured with multiple, direct, and independent methods on the same sample. A conclusion that cardiomyocyte proliferation occurred should be supported by direct quantitative evidence. Stereology is considered by many as the gold standard for quantifying cardiomyocytes in intact hearts (Muhlfeld et al., 2010). Cell cycle outcomes should be determined, i.e. multinucleation, ploidy, and division. Cell cycle activity should be examined and reported separately in diploid-mononucleated and bi-/multinucleated cardiomyocytes, whenever possible. Given the plasticity of cardiomyocytes in culture, timelines of in vitro experiments have to be reported. Karyokinesis and cytokinesis of cultured cardiomyocytes can be documented by video microscopy.

Regenerative cardiac medicine may be able to harness the growing understanding of endogenous cardiomyocyte renewal, stimulated cardiomyocyte proliferation, and progenitor differentiation (Garbern and Lee, 2013; Chong et al., 2014). To address these processes in the tissue context, heterocellular interactions have to be addressed. The extracellular matrix may have a potential function. The injury border region represents a transient space for cellular proliferation. Cardiac stromal cells, including fibroblasts, are known to communicate directly with cardiomyocytes via paracrine factors and cell-to-cell junctions, which may contribute to cell cycle signaling in cardiomyocytes (Ieda et al., 2009).

Acknowledgments

The authors apologize for any references, which were not included in this review. The authors would like to thank funding sources including National Institutes of Health (NIH; F32 HL108570 to S.E.S.; AG032977 and AG040019 to R.L.; U01MH098953, R01HL106302, K08 HL085143 to B.K.), the Department of Cardiology at Boston Children's Hospital, Children's Cardiomyopathy Foundation and the Harold S. Geneen Charitable Trust Award Program (to B.K.).

References

- Adler, C.P., Costabel, U., 1975. Cell number in human heart in atrophy, hypertrophy, and under the influence of cytostatics. *Recent Adv. Stud. Cardiac Struct. Metab.* 6, 343.

- Agah, R., et al., 1997. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. *J. Clin. Invest.* 100, 2722 (Dec 1).
- Ali, S.R., et al., 2014. Existing cardiomyocytes generate cardiomyocytes at a low rate after birth in mice. *Proc. Natl. Acad. Sci. U. S. A.* 111, 8850 (Jun 17).
- Andersen, D.C., Ganesalingam, S., Jensen, C.H., Sheikh, S.P., 2014. Do neonatal mouse hearts regenerate following heart apex resection? *Stem Cell Rep.* 2, 406 (Apr 8).
- Beltrami, A.P., et al., 2001. Evidence that human cardiac myocytes divide after myocardial infarction. *N. Engl. J. Med.* 344, 1750 (Jun 7).
- Bergmann, O., et al., 2009. Evidence for cardiomyocyte renewal in humans. *Science* 324, 98 (Apr 3).
- Bersell, K., Arab, S., Haring, B., Kuhn, B., 2009. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. *Cell* 138, 257 (Jul 23).
- Bersell, K., et al., 2013. Moderate and high amounts of tamoxifen in alphaMHC-MerCreMer mice induce a DNA damage response, leading to heart failure and death. *Dis. Model. Mech.* 6, 1459 (Nov).
- Bettencourt-Dias, M., Mitnacht, S., Brockes, J.P., 2003. Heterogeneous proliferative potential in regenerative adult newt cardiomyocytes. *J. Cell Sci.* 116, 4001 (Oct 1).
- Bicknell, K.A., Coxon, C.H., Brooks, G., 2004. Forced expression of the cyclin B1-CDC2 complex induces proliferation in adult rat cardiomyocytes. *Biochem. J.* 382, 411 (Sep 1).
- Borisov, A.B., Claycomb, W.C., 1995. Proliferative potential and differentiated characteristics of cultured cardiac muscle cells expressing the SV40 T oncogene. *Ann. N. Y. Acad. Sci.* 752, 80 (Mar 27).
- Brooks, G., Poolman, R.A., Li, J.M., 1998. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. *Cardiovasc. Res.* 39, 301 (Aug).
- Buckingham, M.E., Meilhac, S.M., 2011. Tracing cells for tracking cell lineage and clonal behavior. *Dev. Cell* 21, 394 (Sep 13).
- Chakraborty, S., Sengupta, A., Yutzey, K.E., 2013. Tbx20 promotes cardiomyocyte proliferation and persistence of fetal characteristics in adult mouse hearts. *J. Mol. Cell. Cardiol.* 62, 203 (Sep).
- Chaudhry, H.W., et al., 2004. Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. *J. Biol. Chem.* 279, 35858 (Aug 20).
- Chen, Z., Chua, C.C., Ho, Y.S., Hamdy, R.C., Chua, B.H., 2001. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. *Am. J. Physiol. Heart Circ. Physiol.* 280, H2313 (May).
- Chong, J.J., et al., 2014. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* 510 (7504), 273–277 (Apr 30).
- Claycomb, W.C., 1985. Long-term culture and characterization of the adult ventricular and atrial cardiac muscle cell. *Basic Res. Cardiol.* 80 (Suppl. 2), 171.
- Di Stefano, V., Giacca, M., Capogrossi, M.C., Crescenzi, M., Martelli, F., 2011. Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry in the cell cycle. *J. Biol. Chem.* 286, 8644 (Mar 11).
- Dispersyn, G.D., et al., 2002. Dissociation of cardiomyocyte apoptosis and dedifferentiation in infarct border zones. *Eur. Heart J.* 23, 849 (Jun).
- Drenckhahn, J.D., et al., 2008. Compensatory growth of healthy cardiac cells in the presence of diseased cells restores tissue homeostasis during heart development. *Dev. Cell* 15, 521 (Oct).
- Ebelt, H., et al., 2008. E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo. *Cardiovasc. Res.* 80, 219 (Nov 1).
- Ellison, G.M., et al., 2013. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. *Cell* 154, 827 (Aug 15).
- Elser, J.A., Margulies, K.B., 2012. Hybrid mathematical model of cardiomyocyte turnover in the adult human heart. *PLoS One* 7, e51683.
- Engel, F.B., et al., 2005. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. *Genes Dev.* 19, 1175 (May 15).
- Engel, F.B., Hsieh, P.C., Lee, R.T., Keating, M.T., 2006. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. *Proc. Natl. Acad. Sci. U. S. A.* 103, 15546 (Oct 17).
- Flink, I.L., Oana, S., Maitra, N., Bahl, J.J., Morkin, E., 1998. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. *J. Mol. Cell. Cardiol.* 30, 563 (Mar).
- Garbern, J.C., Lee, R.T., 2013. Cardiac stem cell therapy and the promise of heart regeneration. *Cell Stem Cell* 12, 689 (Jun 6).
- Hare, J.M., et al., 2012. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA* 308, 2369 (Dec 12).
- Hashimoto, H., et al., 2014. Time-lapse imaging of cell cycle dynamics during development in living cardiomyocyte. *J. Mol. Cell. Cardiol.* 72C, 241 (Apr 3).
- Haubner, B.J., et al., 2012. Complete cardiac regeneration in a mouse model of myocardial infarction. *Aging (Albany NY)* 4 (966) (Dec).
- Heallen, T., et al., 2013. Hippo signaling impedes adult heart regeneration. *Development* 140, 4683 (Dec).
- Hesse, M., et al., 2012. Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. *Nat. Commun.* 3, 1076.
- Hsieh, P.C., et al., 2007. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. *Nat. Med.* 13, 970.
- Ibrahim, M., Terracciano, C., Yacoub, M.H., 2012. Can bridge to recovery help to reveal the secrets of the failing heart? *Curr. Cardiol. Rep.* 14, 392 (Aug).
- Ieda, M., et al., 2009. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. *Dev. Cell* 16, 233 (Feb).
- Ikenishi, A., et al., 2012. Cell cycle regulation in mouse heart during embryonic and postnatal stages. *Dev. Growth Differ.* 54, 731 (Oct).
- Jopling, C., et al., 2010. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* 464, 606 (Mar 25).
- Katz, E.B., et al., 1992. Cardiomyocyte proliferation in mice expressing alpha-cardiac myosin heavy chain-SV40 T-antigen transgenes. *Am. J. Physiol.* 262, H1867 (Jun).
- Kerkela, R., et al., 2008. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. *J. Clin. Invest.* 118, 3609 (Nov).
- Kikuchi, K., et al., 2010. Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. *Nature* 464, 601 (Mar 25).
- Koitabashi, N., et al., 2009. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. *Circ. Res.* 105, 12 (Jul 2).
- Kubin, T., et al., 2011. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. *Cell Stem Cell* 9, 420 (Nov 4).
- Kuhn, B., et al., 2007. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. *Nat. Med.* 13, 962 (Aug).
- Ladage, D., et al., 2013. Stimulating myocardial regeneration with periostin peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis. *PLoS One* 8, e59656.

- Lesauskaite, V., Epistolato, M.C., Ivanoviene, L., Tanganelli, P., 2004. Apoptosis of cardiomyocytes in explanted and transplanted hearts. Comparison of results from in situ TUNEL, ISEL, and ISOL reactions. *Am. J. Clin. Pathol.* 121, 108 (Jan).
- Lexow, J., Poggioli, T., Sarathchandra, P., Santini, M.P., Rosenthal, N., 2013. Cardiac fibrosis in mice expressing an inducible myocardial-specific Cre driver. *Dis. Model. Mech.* 6, 1470 (Nov).
- Li, F., Wang, X., Capasso, J.M., Gerdes, A.M., 1996. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. *J. Mol. Cell. Cardiol.* 28, 1737 (Aug).
- Li, J.M., Poolman, R.A., Brooks, G., 1998. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. *Am. J. Physiol.* 275, H814 (Sep).
- Liao, H.S., et al., 2001. Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiomyocytes. *Circ. Res.* 88, 443 (Mar 2).
- Linzbach, A.J., 1950. The muscle fiber constant and the law of growth of the human ventricles. *Virchows Arch.* 318, 575.
- Linzbach, A.J., 1960. Heart failure from the point of view of quantitative anatomy. *Am. J. Cardiol.* 5, 370 (Mar).
- Litvin, J., et al., 2006. Periostin and periostin-like factor in the human heart: possible therapeutic targets. *Cardiovasc. Pathol.* 15, 24 (Jan-Feb).
- Liu, Y., Kitsis, R.N., 1996. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. *J. Cell Biol.* 133, 325 (Apr).
- Loffredo, F.S., Steinhauser, M.L., Gannon, J., Lee, R.T., 2011. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. *Cell Stem Cell* 8, 389 (Apr 8).
- Lorts, A., Schwanekamp, J.A., Elrod, J.W., Sargent, M.A., Molkentin, J.D., 2009. Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. *Circ. Res.* 104, e1 (Jan 2).
- MacLellan, W.R., et al., 2005. Overlapping roles of pocket proteins in the myocardium are unmasked by germ line deletion of p130 plus heart-specific deletion of Rb. *Mol. Cell. Biol.* 25, 2486 (Mar).
- Mahmoud, A.I., et al., 2013. Meis1 regulates postnatal cardiomyocyte cell cycle arrest. *Nature* 497 (7448), 249–253 (Apr 17).
- Malliaras, K., et al., 2013. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. *EMBO Mol. Med.* 5 (2), 191–209 (Dec 19).
- Mollova, M., et al., 2013. Cardiomyocyte proliferation contributes to heart growth in young humans. *Proc. Natl. Acad. Sci. U. S. A.* 110 (4), 1446–1451 (Jan 9).
- Muhlfeld, C., Nyengaard, J.R., Mayhew, T.M., 2010. A review of state-of-the-art stereology for better quantitative 3D morphology in cardiac research. *Cardiovasc. Pathol.* 19, 65 (Mar-Apr).
- Naqvi, N., et al., 2014. A proliferative burst during preadolescence establishes the final cardiomyocyte number. *Cell* 157, 795 (May 8).
- Oberpriller, J.O., Oberpriller, J.C., 1974. Response of the adult newt ventricle to injury. *J. Exp. Zool.* 187, 249 (Feb).
- Pasumarthi, K.B., Field, L.J., 2002. Cardiomyocyte cell cycle regulation. *Circ. Res.* 90, 1044 (May 31).
- Pasumarthi, K.B., Nakajima, H., Nakajima, H.O., Soonpaa, M.H., Field, L.J., 2005. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. *Circ. Res.* 96, 110 (Jan 7).
- Polizzotti, B.D., Arab, S., Kuhn, B., 2012. Intrapericardial delivery of gelfoam enables the targeted delivery of periostin peptide after myocardial infarction by inducing fibrin clot formation. *PLoS One* 7, e36788.
- Poolman, R.A., Brooks, G., 1998. Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. *J. Mol. Cell. Cardiol.* 30, 2121 (Oct).
- Porrello, E.R., et al., 2011. Transient regenerative potential of the neonatal mouse heart. *Science* 331, 1078 (Feb 25).
- Porrello, E.R., et al., 2012. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. *Proc. Natl. Acad. Sci. U. S. A.* 110, 187 (Jan 2).
- Porrello, E.R., et al., 2013. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. *Proc. Natl. Acad. Sci. U. S. A.* 110, 187 (Jan 2).
- Poss, K.D., Wilson, L.G., Keating, M.T., 2002. Heart regeneration in zebrafish. *Science* 298, 2188 (Dec 13).
- Puente, B.N., et al., 2014. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. *Cell* 157, 565 (Apr 24).
- Rios, H., et al., 2005. Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. *Mol. Cell. Biol.* 25, 11131 (Dec).
- Rumyantsev, P.P., Carlson, B.M., 1991. Growth and hyperplasia of cardiac muscle cells. Soviet medical reviews. Supplement series. *Cardiology.* Harwood Academic Publishers, London, U.K. ; New York, N.Y., U.S.A, p. 376.
- Sadek, H.A., et al., 2014. Multi-investigator letter on reproducibility of neonatal heart regeneration following apical resection. *Stem Cell Rep.* 3, 1 (Jul 8).
- Saraste, A., Pulkki, K., 2000. Morphologic and biochemical hallmarks of apoptosis. *Cardiovasc. Res.* 45, 528 (Feb).
- Sdek, P., et al., 2011. Rb and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes. *J. Cell Biol.* 194, 407 (Aug 8).
- Senyo, S.E., et al., 2013. Mammalian heart renewal by pre-existing cardiomyocytes. *Nature* 493, 433 (Jan 17).
- Sharov, V.G., et al., 1997. Abnormalities of cardiocytes in regions bordering fibrous scars of dogs with heart failure. *Int. J. Cardiol.* 60, 273 (Aug 8).
- Shimazaki, M., et al., 2008. Periostin is essential for cardiac healing after acute myocardial infarction. *J. Exp. Med.* 205, 295 (Feb 18).
- Sohal, D.S., et al., 2001. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. *Circ. Res.* 89, 20 (Jul 6).
- Soonpaa, M.H., Field, L.J., 1997. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. *Am. J. Physiol. Heart Circ. Physiol.* 272, H220.
- Soonpaa, M.H., Kim, K.K., Pajak, L., Franklin, M., Field, L.J., 1996. Cardiomyocyte DNA synthesis and binucleation during murine development. *Am. J. Physiol.* 271, H2183 (Nov).
- Soonpaa, M.H., et al., 1997. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. *J. Clin. Invest.* 99, 2644 (Jun 1).
- Soonpaa, M.H., Rubart, M., Field, L.J., 2012. Challenges measuring cardiomyocyte renewal. *Biochim. Biophys. Acta* 1833, 799 (Apr).
- Steinhauser, M.L., Lechene, C.P., 2013. Quantitative imaging of subcellular metabolism with stable isotopes and multi-isotope imaging mass spectrometry. *Semin. Cell Dev. Biol.* 24, 661 (Aug-Sep).
- Steinhauser, M.L., et al., 2012. Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. *Nature* 481, 516 (Jan 26).
- Tang, Y., Nyengaard, J.R., Andersen, J.B., Baandrup, U., Gundersen, H.J., 2009. The application of stereological methods for estimating structural parameters in the human heart. *Anat. Rec. (Hoboken)* 292 (1630) (Oct).
- Tang, H.L., et al., 2012. Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. *Mol. Biol. Cell* 23, 2240 (Jun).
- Traverse, J.H., et al., 2012. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. *JAMA* 308, 2380 (Dec 12).
- Tsang, V., et al., 2009. Late donor cardiectomy after paediatric heterotopic cardiac transplantation. *Lancet* 374, 387 (Aug 1).

- Tseng, A.S., Engel, F.B., Keating, M.T., 2006. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. *Chem. Biol.* 13, 957 (Sep).
- van Berlo, J.H., et al., 2014. c-kit⁺ cells minimally contribute cardiomyocytes to the heart. *Nature* 509, 337 (May 15).
- von Gise, A., et al., 2012. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. *Proc. Natl. Acad. Sci. U. S. A.* 109, 2394 (Feb 14).
- Vulapalli, S.R., Chen, Z., Chua, B.H., Wang, T., Liang, C.S., 2002. Cardiospecific overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. *Am. J. Physiol. Heart Circ. Physiol.* 283, H688 (Aug).
- Wadugu, B., Kuhn, B., 2012. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. *Am. J. Physiol. Heart Circ. Physiol.* 302, H2139 (Jun 1).
- Walsh, S., Ponten, A., Fleischmann, B.K., Jovinge, S., 2010. Cardiomyocyte cell cycle control and growth estimation in vivo—an analysis based on cardiomyocyte nuclei. *Cardiovasc. Res.* 86, 365 (Jun 1).
- Wencker, D., et al., 2003. A mechanistic role for cardiac myocyte apoptosis in heart failure. *J. Clin. Invest.* 111, 1497 (May).
- Wills, A.A., Holdway, J.E., Major, R.J., Poss, K.D., 2008. Regulated addition of new myocardial and epicardial cells fosters homeostatic cardiac growth and maintenance in adult zebrafish. *Development* 135, 183 (Jan).
- Wilson, A., et al., 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* 135, 1118 (Dec 12).
- Woo, Y.J., et al., 2006. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. *Circulation* 114, I206 (Jul 4).
- Xin, M., et al., 2011. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. *Sci. Signal.* 4, ra70.
- Yurkova, N., et al., 2008. The cell cycle factor E2F-1 activates Bnip3 and the intrinsic death pathway in ventricular myocytes. *Circ. Res.* 102, 472 (Feb 29).
- Zak, R., 1973. Cell proliferation during cardiac growth. *Am. J. Cardiol.* 31, 211 (Feb).
- Zaruba, M.M., Soonpaa, M., Reuter, S., Field, L.J., 2010. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. *Circulation* 121, 1992 (May 11).
- Zhang, Y., et al., 2010. Dedifferentiation and proliferation of mammalian cardiomyocytes. *PLoS One* 5, e12559.